# 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

> **NCT07549646** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Hospital of Philadelphia** · enrollment: 45 (estimated)

## Conditions studied

- Ras/MAPK Pathway Vascular Anomalies
- Vascular Anomalies
- Vascular Anomaly

## Interventions

- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT07549646
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-27
- **Primary completion:** 2029-08-27
- **Final completion:** 2030-08-27
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549646, "24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07549646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*